Locations:
Search IconSearch
December 4, 2023/Cancer

First of Its Kind: Oncology Pharmacovigilance Clinic

Multidisciplinary care for patients with immune-related adverse events

TaussigCC_650x450

By Cassandra Calabrese, DO

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The cancer treatment landscape was forever changed in 2011 with approval of the first checkpoint inhibitor, nivolumab. These drugs rev up the immune system to target tumor cells and have provided options for durable treatment responses for patients with previously untreatable cancers.

Unfortunately, due to their mechanism, they are attended by a spectrum of adverse events that mimic immune-mediated diseases (such as rheumatoid arthritis and colitis), and these are called immune-related adverse events (irAEs). With the increasing approval of new checkpoint inhibitor therapies for an ever-expanding list of indications, we are seeing a rise in referrals for irAE diagnosis and management in rheumatology and other specialties.

In 2017, Cleveland Clinic created a multidisciplinary monthly tumor board, which continues to serve as a venue for discussion of challenging cases, review the extant literature and receive input on interprofessional management. In the past year, almost on- third of the cases discussed at irAE tumor board are rheumatologic irAE cases.

Major academic centers have varying triage and referral processes for care of patients with irAEs. Cleveland Clinic is the first to create a multidisciplinary clinic to serve this purpose. In September 2023, the Oncology Pharmacovigilance Clinic was created in the Taussig Cancer Center under the guidance of Wen Wee Ma, MBBS, the inaugural Director of the Novel Cancer Therapeutics Center in Taussig. This clinic is in Taussig and occurs one half-day per week. It is staffed by myself, endocrinologist Keren Zhou, MD, and coordinated with Oncology.

Patients with irAEs are often acutely symptomatic, with symptoms interfering with activities of daily living and disrupting their cancer treatment. Many are experiencing irAEs involving multiple systems. For these reasons, it is important there be timely access for their evaluation by Oncology and appropriate subspecialists, and ideally in a coordinated fashion.

The goal of the Pharmacovigilance Clinic is to serve as a space for exactly that, fostering excellent patient care and in-person interactions between subspecialists. This type of clinic for irAE care exists nowhere else in the world, and we are proud to be involved in this ground-breaking endeavor.

After this initial phase, the goal is to introduce additional specialists such as gastroenterology, cardiology and beyond.

Advertisement

Related Articles

Dr. Holly Pederson
July 25, 2024/Cancer/Research
Evaluating Risk Scores for Triple-Negative Breast Cancer in Black Women (Podcast)

Polygenic risk score could help predict who will develop this aggressive breast cancer

Reviewing dental scans
July 8, 2024/Cancer
A Call for More Interdisciplinary and Preventive Care in New Osteoradionecrosis Guidelines

New guidelines offer insight into emerging therapies, dental issues and more

Dr. AlHilli
July 3, 2024/Cancer/Patient Support
Prehabilitation Program Aims to Improve Outcomes for Older Patients with Ovarian or Pancreatic Cancer

Clinical trial to assess the value of nutritional, physical therapy and social supports prior to preoperative chemotherapy

Dr. Nahleh
June 26, 2024/Cancer/Patient Support
Systemic Treatment a Major Factor Impacting Survival of Patients with Breast Cancer with Brain Metastasis

Research demonstrates improved overall survival for patients receiving comprehensive treatment for breast cancer in addition to radiation or surgical intervention for brain cancer

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Dr. Grobmyer and team
June 14, 2024/Cancer/Innovations
Fatima bint Mubarak Center Addresses Inequities in Cancer Care

Cleveland Clinic Cancer Institute brings multidisciplinary care, precision oncology and clinical research to the United Arab Emirates

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

Ad